$ADHD to Present at Upcoming Investment Conferences

0
890

Alcobra Ltd. to Present at Upcoming Investment Conferences Company Will Host Corporate Update Conference Call & Webcast on November 17

 

Alcobra Ltd. (ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced upcoming corporate presentations at the Stifel 2015 Healthcare Conference and the Jefferies Autumn 2015 Global Healthcare Conference. The company will host a conference call and webcast on November 17 to provide a corporate update and discuss third quarter 2015 financial results.

Conference Call & Webcast
Tuesday, November 17 @ 8:30am Eastern
Domestic: 855-469-0611
International: 484-756-4341
Passcode: 56489875
Webcast: http://www.alcobra-pharma.com/events.cfm
Replays available through December 1, 2015
Domestic: 855-859-2056
International: 404-537-3406
Passcode: 56489875
Stifel 2015 Healthcare Conference
Date: Tuesday, November 17
Time: 11:00am ET
Location: Lotte New York Palace, New York, NY
Presenter: Dr. Yaron Daniely, CEO
Webcast: www.veracast.com/webcasts/stifel/healthcare2015/91105605087.cfm
Jefferies Autumn 2015 Global Healthcare Conference
Date: Thursday, November 19
Time: 12:40pm GMT (7:40 am ET)
Location: The Mayfair Hotel, London, UK
Presenter: Dr. Yaron Daniely, CEO
Webcast: http://wsw.com/webcast/jeff92/adhd/index.aspx

About Alcobra Ltd.

Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and FXS. For more information please visit the Company’s website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.

Contact:
U.S. Investor Contacts
LifeSci Advisors, LLC
Michael Rice
646-597-6979
[email protected]
Media Inquiries
Sam Brown, Inc.
Mike Beyer
312-961-2502
[email protected]
Israel Investor Contact:
Alcobra Investor Relations
Debbie Kaye
+972-72 2204661
[email protected]

LEAVE A REPLY

Please enter your comment!
Please enter your name here